Promising new drug targets solid tumors; phase 1A clinical trials successfully completed By Michele Sequeira — October 02, 2017 Categories: Cancer Center Patient Care Albuquerque, NM — The University of New Mexico Comprehensive Cancer Center played a key role in the [...]
Bexion Pharmaceuticals and CTI Clinical Trial and Consulting Services Announce Completion of First-in-Human Trial Using BXQ-350 for the Treatment of Cancer
Covington, KY - Bexion Pharmaceuticals (Bexion) and CTI Clinical Trial and Consulting Services (CTI) announce the successful completion of the First-in-Human Phase IA clinical trial with BXQ-350 for the treatment of cancer. This dose escalation, open-label [...]
Covington, KY - Bexion Pharmaceuticals was awarded the “Medical Professional Award” at the American Cancer Society’s Annual Striders’ Ball held on November 5, 2016. This is the first time the honor has been bestowed on a [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857